UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549


FORM 8-K


CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported):   February 4, 2011


PACIFICHEALTH LABORATORIES, INC.
(Exact Name of Registrant as Specified in Its Charter)


Delaware
000-23495
22-3367588
(State or Other Jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification Number)
     
100 Matawan Road, Suite 150, Matawan, NJ
07747-3913
(Address of Principal Executive Offices)
(Zip Code)

 
Registrant’s telephone number, including area code:   (732) 739-2900


N/A
(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 1.01
Entry into a Material Definitive Agreement.

On February 4, 2011, PacificHealth Laboratories, Inc. (the “ Registrant ”) entered into a consulting agreement (the “ Agreement ”) with Signal Nutrition LLC (“ Signa l”).  Robert Portman, a Director of the Registrant is the sole member of Signal. Under the terms of the Agreement, Signal will work with outside researchers on behalf of the Registrant, assist the Registrant in developing new products, and formulate sales and marketing plans.  The Agreement has an indefinite term with an option by either party to terminate the agreement on thirty (30) days notice.  The Registrant will pay Signal a fee of $16,000 per month, commencing March 1, 2011, during the term of the Agreement.

The foregoing description is a summary and is qualified in its entirety by a copy of the Agreement attached as Exhibit 10.1 hereto and incorporated by reference herein.

Item 9.01. 
Financial Statements and Exhibits

 (d) 
Exhibits

10.1           Consulting Agreement dated February 4, 2011 by and between PacificHealth Laboratories, Inc. and Signal Nutrition LLC.


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  PACIFICHEALTH LABORATORIES, INC.  
       
Dated:  February 8, 2011
By:
/s/ Stephen P. Kuchen  
    Stephen P. Kuchen  
    Chief Financial Officer  
 
 
2
 
 
PacificHealth Laboratories (CE) (USOTC:PHLI)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse PacificHealth Laboratories (CE)
PacificHealth Laboratories (CE) (USOTC:PHLI)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse PacificHealth Laboratories (CE)